Health
FDA requires GLP-1 drugs to warn about potential vision loss risk.
NAION is an eye stroke that can cause sudden, permanent vision loss and has no proven treatment.
OriginalSourceGizmodoUnited StatesLeanUnratedCredibilityUnratedPublished21:46 UTCSourceGizmodoUnited StatesLeanUnratedCredibilityUnratedPublished21:46 UTC
“FDA Orders New Vision Loss Warning for Ozempic and Other GLP-1s”
“Health regulators have found a consistent link between GLP-1 use and the eye condition NAION.”
FDA warns GLP-1 drugs may be linked to NAION vision loss
Key points
- FDA orders warning on labeling for semaglutide and other GLP-1s about NAION.
- NAION is a rare, potentially permanent vision loss from reduced optic nerve blood flow.
- Higher risk seen in people over 50 with hypertension; absolute risk still low.
- European agencies independently flagged GLP-1 NAION as very rare, up to 1 in 10,000.
- Patients should monitor vision changes and consult doctors promptly if affected.
Other reports
- SourceSTATUnited StatesLeanCenterCredibilityRatings: AllSides, MBFCRead at STATSourceSTATUnited StatesLeanCenterCredibilityRatings: AllSides, MBFCRead at STAT
“STAT+: FDA warns GLP-1 drugs carry potential risk of rare eye condition”
- SourceMarketWatchUnited StatesOwner: Dow Jones & CompanyLeanCenterCredibilityRatings: AllSides, MBFCRead at MarketWatchSourceMarketWatchUnited StatesOwner: Dow Jones & CompanyLeanCenterCredibilityRatings: AllSides, MBFCRead at MarketWatch
“Ozempic, Zepbound and other GLP-1 drugs have a possible risk of vision loss”
- SourceQuartzUnited StatesLeanUnratedCredibilityUnratedRead at QuartzSourceQuartzUnited StatesLeanUnratedCredibilityUnratedRead at Quartz
“FDA is requiring weight loss drug makers to add a vision loss warning”
- SourceThe IndependentUnited KingdomLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at The IndependentSourceThe IndependentUnited KingdomLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at The Independent
- SourceAP NewsUnited StatesLeanCenterCredibilityRatings: AllSides, MBFCRead at AP NewsSourceAP NewsUnited StatesLeanCenterCredibilityRatings: AllSides, MBFCRead at AP News
- SourceThe Washington PostUnited StatesLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at The Washington PostSourceThe Washington PostUnited StatesLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at The Washington Post
“FDA tells GLP-1 makers to warn of potential vision loss side effect”
- SourceNew York PostUnited StatesLeanCenter-rightCredibilityRatings: AllSides, MBFCRead at New York PostSourceNew York PostUnited StatesLeanCenter-rightCredibilityRatings: AllSides, MBFCRead at New York Post
“GLP-1 drugs must have new warning label over incurable blindness condition, says FDA”
- SourceCBS NewsUnited StatesLeanUnratedCredibilityUnratedRead at CBS NewsSourceCBS NewsUnited StatesLeanUnratedCredibilityUnratedRead at CBS News
“FDA warns of rare vision-loss side effect from GLP-1 drugs”
How it got here
Gizmodo publishes the article.
concise.news reads it.
Grouped with 8 other reports as story 9.
The Brief ranks it 9th.
9 9 FDA requires GLP-1 drugs to warn about potential vision loss risk.
NAION is an eye stroke that can cause sudden, permanent vision loss and has no proven treatment.